

IN THE CLAIMS:

1. (Currently Amended) A pharmaceutical composition comprising:
a biocompatible carrier for injection or infusion, and an isolated and purified N-terminal fragment of
agglutinin like sequences (ALS1) cell surface adhesin protein obtained from *Candida albicans*,
wherein the composition vaccine produces an effective immune response in a patient.
2. (Cancelled)
3. (Previously Presented) The composition of Claim 1, wherein the protein
contains an adhesin binding site of *Candida albicans*.
- 4-8. (Cancelled)
9. (Currently Amended) The composition of claim 1 wherein the ~~N-terminal fragment~~
ALS1 protein is encoded by nucleotides 52 to 1296 of SEQ ID No. 7.
10. (New) A pharmaceutical composition consisting essentially of:
a biocompatible carrier for injection or infusion, and an isolated and purified N-
terminal fragment of agglutinin like sequences (ALS1) cell surface adhesin protein obtained from
Candida albicans, wherein the composition produces an effective immune response in a patient.
11. (New) The composition of Claim 1, wherein the protein contains an adhesin binding
site of *Candida albicans*.
12. (New) The composition of claim 1 wherein the ~~N-terminal fragment~~ ALS1 protein is
encoded by nucleotides 52 to 1296 of SEQ ID No. 7.